Ichnos Glenmark's Trispecific Antibody Shows Promise in Relapsed/Refractory Multiple Myeloma

• Ichnos Glenmark Innovation's trispecific antibody demonstrates a promising profile in treating relapsed/refractory multiple myeloma, offering a potential advancement over existing bispecific antibodies.
• Early-stage trials reveal a significant overall response rate, indicating the antibody's potential efficacy in patients with limited treatment options.
• The trispecific antibody targets multiple myeloma, presenting a novel approach to combatting this challenging hematological malignancy.
• The company is optimistic about the antibody's prospects and is closely monitoring its performance in ongoing clinical trials.

Ichnos Glenmark Innovation is developing a trispecific antibody that shows promise in treating relapsed/refractory multiple myeloma. Early data suggests the antibody may offer advantages over existing bispecific antibodies, including a significant overall response rate.

Cyril Konto, President and CEO of Ichnos Glenmark Innovation, highlighted the promising profile of the trispecific antibody. The company is closely monitoring the antibody's performance in ongoing clinical trials, with hopes of providing a new treatment option for patients with multiple myeloma.

Multiple myeloma remains a challenging hematological malignancy, and new therapeutic strategies are needed to improve patient outcomes. The development of this trispecific antibody represents a novel approach to targeting multiple myeloma cells and potentially overcoming resistance to existing therapies. The full data will be presented at ASH 2024.